|
Volume
|
Parameter
|
AP-1
|
AP-2
|
TM
|
BM
|
Original plan
|
|---|
|
CTV1
|
V95 (%)
|
99.4 (95.6–99.9)
|
97.5(94.3–99.4)
|
88.3 (79.4–97.5)*
|
84.8 (67.7–96.7)*
|
99.5 (93.0–99.9)
|
| |
V90 (%)
|
99.9 (99.1–100)
|
99.5 (98.7–100)
|
94.7 (89.1–99.7)*
|
91.2 (76.4–99.4)*
|
100 (97.8–100)
|
| |
D98 [Gy (RBE)]
|
40.1(38.4–40.8)
|
39.1 (37.9–40.3)
|
35.5 (32.1–39.1)*
|
33.0 (22.8–38.8)*
|
40.2 (37.1–40.7)
|
| |
Mean [Gy (RBE)]
|
41.4 (41.1–42.0)
|
41.3 (41.1–41.5)
|
40.9 (40.2–41.2)*
|
40.6 (38.5–41.1)*
|
41.4 (41.1–41.7)
|
|
CTV2
|
V95 (%)
|
96.7 (85.1–99.8)
|
91.8 (82.5–98.4)*
|
85.1 (81.0–98.3)*
|
80.5 (37.1–95.1)*
|
93.5 (86.1–100)
|
| |
V90 (%)
|
99.0 (91.1–100)
|
96.6 (88.5–99.8)
|
94.4 (89.9–99.6)
|
89.4 (46.5–98.3)*
|
98.5 (91.3–100)
|
| |
D98 [Gy (RBE)]
|
51.2 (43.8–54.5)
|
48.3 (44.4–52.8)
|
46.3 (43.4–52.8)
|
44.7 (21.6–50.0)*
|
49.3 (43.3–54.6)
|
| |
Mean [Gy (RBE)]
|
55.0 (54.3–55.4)
|
54.7 (54.0–55.2)*
|
54.4 (53.9–55.2)*
|
53.8 (44.6–54.9)*
|
54.8 (54.3–55.3)
|
|
GTV
|
V95 (%)
|
99.0 (88.2–100)
|
97.3 (90.7–100)
|
94.9 (85.8–100)
|
90.5 (44.4–100)*
|
98.5 (85.6–100)
|
| |
V90 (%)
|
99.8 (93.5–100)
|
99.6 (96.4–100)
|
99.0 (94.5–100)
|
96.7 (53.5–100)*
|
99.6 (90.9–100)
|
| |
D98 [Gy (RBE)]
|
53.6 (45.5–55.3)
|
52.1 (47.8–55.0)
|
50.8 (47.6–55.1)
|
48.0 (28.4–54.9)*
|
52.3 (43.3–55.1)
|
| |
Mean [Gy (RBE)]
|
55.2 (54.8–55.6)
|
55.1 (54.5–55.5)
|
55.0 (54.3–55.4)
|
54.6 (47.3–55.4)*
|
55.1 (54.3–55.5)
|
|
Duodenum
|
D2cc [Gy (RBE)]
|
28.5 (18.5–36.3)
|
32.1 (22.2–49.8)*
|
27.2 (20.8–47.4)
|
31.1 (18.2–46.9)
|
25.2 (21.3–40.2)
|
| |
V10 [Gy (RBE)] (ml)
|
36.8 (21.8–79.5)
|
37.1 (22.5–82.5)
|
40.7 (24.3–79.0)
|
38.2 (27.7–81.0)
|
41.2 (22.5–82.7)
|
| |
V20 [Gy (RBE)] (ml)
|
7.0 (1.7–25.6)
|
11.0 (3.1–52.2)*
|
5.6 (2.1–29.6)*
|
7.2 (0.9–25.5)*
|
3.5 (2.3–20.1)
|
| |
V30 [Gy (RBE)] (ml)
|
1.4 (0.5–10.6)
|
2.9 (0.2–19.7)
|
1.9 (0.3–13.2)
|
2.5 (0.0–10.3)
|
1.0 (0.4–9.5)
|
| |
Mean [Gy (RBE)]
|
11.4 (6.8–15.1)
|
12.8 (7.8–22.4)
|
10.7 (7.8–20.5)
|
11.6 (7.8–19.2)
|
10.1 (7.7–15.6)
|
|
Stomach
|
D2cc [Gy (RBE)]
|
35.2 (19.0–40.1)
|
38.4 (23.7–42.3)
|
34.0 (18.9–38.4)
|
35.3 (21.1–44.0)
|
36.0 (16.9–43.6)
|
| |
V10 [Gy (RBE)] (ml)
|
73.4 (23.3–106.1)
|
73.9 (26.1–106.3)
|
71.3 (17.2–107.6)
|
65.4 (19.2–100.1)
|
82.5 (20.9–113.8)
|
| |
V20 [Gy (RBE)] (ml)
|
14.2 (1.7–45.2)
|
20.3 (3.8–48.9)
|
17.4 (1.6–49.7)
|
20.8 (2.4–45.4)
|
15.7 (1.1–51.2)
|
| |
V30 [Gy (RBE)] (ml)
|
4.7 (0.2–18.0)
|
6.6 (0.6–21.6)
|
5.4 (0.1–22.3)
|
5.1 (0.3–20.7)
|
6.3 (0.1–26.9)
|
| |
Mean [Gy (RBE)]
|
7.6 (3.5–16.9)
|
7.6 (3.9–17.8)
|
7.3 (2.8–17.7)
|
6.8 (3.2–16.6)
|
8.9 (2.9–18.9)
|
- Data are presented as median (range)
- TM tumor matching, BM bone matching, CTV clinical target volume, GTV gross tumor volume, V95 and V90 the percentage of the volume receiving 95% and 90% of prescribed dose, D98 the dose coverage 98% of the volume. Vn the absolute volume receiving n Gy (RBE)
- *P < 0.05 compared with original plan
